Research & Development
Vanda's NEREUS approved by US FDA for prevention of motion sickness
31 December 2025 - Vanda Pharmaceuticals Inc (Nasdaq:VNDA), a US-based global biopharmaceutical company, announced on Tuesday that it has received approval from the US Food and Drug Administration (FD...
Diamyd Medical agrees accelerated efficacy readout in ongoing Phase 3 type 1 diabetes trial
30 December 2025 - Swedish biotechnology company Diamyd Medical AB (Nasdaq First North Growth Market:DMYD-B) said on Monday that it has reached alignment with the US Food and Drug Administration (FDA)...
INOVIO's INO-3107 Biologics License Application accepted by US FDA
30 December 2025 - Biotechnology company INOVIO (NASDAQ:INO) announced on Monday that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for INO-3107 for re...
Citius Pharmaceuticals reports full-year financial results
24 December 2025 - Late-stage biopharmaceutical company Citius Pharmaceuticals Inc (Nasdaq:CTXR) announced on Tuesday its financial results for the fiscal year ended 30 September 2025.Citius Pharma di...
Bioeq and Zydus partner for US commercialisation of Lucentis biosimilar NUFYMCO
24 December 2025 - Swiss biopharmaceutical company Bioeq AG and India-based life-sciences company Zydus Lifesciences Limited announced on Tuesday that Zydus's wholly owned subsidiary, Zydus Lifes...
Sanofi receives FDA complete response letter for tolebrutinib in progressive MS
24 December 2025 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) said on Wednesday that the US Food and Drug Administration (FDA) has issued a complete response letter for th...